Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on A...
02 Aprile 2019 - 1:00PM
Innovate plans to provide an operational progress
update, including regarding its first phase 3 celiac disease
clinical trial
Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage
biotechnology company focused on developing novel therapeutics for
autoimmune and inflammatory diseases with its lead drug, larazotide
acetate, comprising a new class of medicines based on
gut-restricted peptides which re-normalize the gut-epithelial
barrier and the gut-liver axis, announced today it intends to host
an audio webcast on Monday, April 29, 2019, at 8:00 a.m. ET, to
report financial results for the first quarter ended March 31, 2019
and provide an operational progress update, including with respect
to its first phase 3 celiac disease clinical trial.
Please visit the Investor section of Innovate’s website for
further details on how accessing the webcast.
Event: |
|
Webcast to report preliminary financial
results for the first quarter ended March 31, 2019, and to provide
operational progress updates |
Date: |
|
Monday, April 29, 2019 |
Time: |
|
8:00am ET |
A live and archived audio webcast of the conference call will be
available on the Events and Presentations page of the Innovate’
corporate website at www.innovatebiopharma.com.
About larazotide acetate for celiac disease In
celiac disease, larazotide is the only drug which has successfully
met its primary endpoint with statistical significance in a Phase
2b efficacy clinical trial (342 patients). Innovate completed the
End of Phase 2 Meeting with the FDA and is preparing to launch the
Phase 3 registration clinical trials for celiac disease in the
second quarter of 2019. Nearly 600 subjects have been exposed to
larazotide in clinical trials, and a safety profile comparable to
placebo has been demonstrated. Larazotide has received Fast Track
designation from the FDA for celiac disease
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT) Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for autoimmune and
inflammatory diseases. Innovate’s lead drug candidate, larazotide
acetate, has a mechanism of action that renormalizes the
dysfunctional intestinal barrier by decreasing intestinal
permeability and reducing antigen trafficking, such as gliadin
fragments in celiac disease, and bacterial toxins and immunogenic
antigens in nonalcoholic steatohepatitis (NASH). In several
diseases, including celiac disease, NASH, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes
mellitus (T1DM), chronic kidney disease (CKD), the intestinal
barrier is dysfunctional with increased permeability.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to the development of drug candidates, our
operations and business strategy, our expected financial results,
and corporate updates. The forward-looking statements contained in
this press release are based on management’s current expectations
and are subject to substantial risks, uncertainty and changes in
circumstances. Actual results may differ materially from those
expressed by these expectations due to risks and uncertainties,
including, among others, those related to our ability to obtain
additional capital on favorable terms to us, or at all, including,
without limitation, to fund our current and future preclinical
studies and clinical trials and the success, timing and cost of our
drug development program and our ongoing or future preclinical
studies and clinical trials, including, without limitation, the
possibility of unfavorable new clinical and preclinical data and
additional analyses of existing data, as well as the risks that
prior clinical and preclinical results may not be replicated. These
risks and uncertainties include, but may not be limited to, those
described in our Annual Report on Form 10-K filed with
the SEC on March 18, 2019, and in any subsequent
filings with the SEC. Forward-looking statements speak only as
of the date of this press release, and we undertake no obligation
to review or update any forward-looking statement except as may be
required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Contact: Jennifer K. Zimmons, Ph.D. Investor
Relations Tel: +1-917-214-3514 Email:
jzimmons@innovatebiopharma.com www.innovatebiopharma.com
Grafico Azioni Innovate Biopharmaceutic... (NASDAQ:INNT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Innovate Biopharmaceutic... (NASDAQ:INNT)
Storico
Da Giu 2023 a Giu 2024